Genomic Valley Biotech Intrinsic Value
GVBL Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹7.71 | ₹6.17 - ₹9.25 | -70.0% | EPS: ₹0.30, Sector P/E: 22x |
| Book Value Method | asset | ₹26.67 | ₹24.00 - ₹29.34 | +3.8% | Book Value/Share: ₹13.33, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹7.71 | ₹6.94 - ₹8.48 | -70.0% | Revenue/Share: ₹3.33, P/S: 2.0x |
| PEG Ratio Method | growth | ₹7.71 | ₹6.94 - ₹8.48 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹7.71 | ₹6.94 - ₹8.48 | -70.0% | Revenue Growth: -30.0%, Adj P/E: 12.8x |
| Graham Defensive Method | conservative | ₹9.49 | ₹8.54 - ₹10.44 | -63.1% | EPS: ₹0.30, BVPS: ₹13.33 |
Want to compare with current market value? Check GVBL share price latest .
Valuation Comparison Chart
GVBL Intrinsic Value Analysis
What is the intrinsic value of GVBL?
Based on our comprehensive analysis using 6 different valuation methods, the estimated intrinsic value of Genomic Valley Biotech (GVBL) is ₹7.71 (median value). With the current market price of ₹25.69, this represents a -70.0% variance from our estimated fair value.
The valuation range spans from ₹7.71 to ₹26.67, indicating ₹7.71 - ₹26.67.
Is GVBL undervalued or overvalued?
Based on our multi-method analysis, Genomic Valley Biotech (GVBL) appears to be trading above calculated value by approximately 70.0%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Debt to Equity Ratio | 1.00 | Industry Standard: <0.5 | Below 1.0 | Indicates financial leverage level |
| Operating Margin | 27.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.25x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
Related Pages for Genomic Valley Biotech
Additional stock information and data for GVBL
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹-1 Cr | ₹-1 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹-2 Cr | ₹-2 Cr | Negative Cash Flow | 3/10 |
| March 2021 | ₹2 Cr | ₹1 Cr | Positive Free Cash Flow | 7/10 |